In vitro and in vivo osteoblastic differentiation of BMP-2- and Runx2-engineered skeletal myoblasts

Journal of Cellular Biochemistry

Volumn 100, Issue 5, 2007, Pages 1324-1336

  Gersbach, Charles A ^a,c   Guldberg, Robert E ^b,c   García, Andrés J ^b,c  

^a Emory University   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Bone tissue engineering; Ectopic implantation; Gene therapy; Orthopedic regeneration; Retrovirus; Skeletal myoblasts; Transcription factor

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; COLLAGEN; SCAFFOLD PROTEIN; SMAD PROTEIN; TRANSCRIPTION FACTOR RUNX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE MINERALIZATION; CELL DIFFERENTIATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENETIC ENGINEERING; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOLAYER CULTURE; MOUSE; MYOBLAST; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE ENGINEERING; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; MUSCLE DEVELOPMENT; MYOBLASTS, SKELETAL; OSTEOBLASTS; OSTEOGENESIS; PARACRINE COMMUNICATION; RETROVIRIDAE; RNA, MESSENGER; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33947598873     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21118     Document Type: Article

References (63)

1. Baltzer AW, Lieberman JR. 2004. Regional gene therapy to enhance bone repair. Gene Ther 11:344-350.
2. Bruder SP, Fox BS. 1999. Tissue engineering of bone. Cell based strategies. Clin Orthop 367(Suppl):S68-S83.
3. Bruder SP, Jaiswal N, Haynesworth SE. 1997. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem 64:278-294.
4. Bucholz RW. 2002. Nonallograft osteoconductive bone graft substitutes. Clin Orthop 395:44-52.
5. Byers BA, Pavlath GK, Murphy TJ, Karsenty G, Garcia AJ. 2002. Cell-type-dependent up-regulation of in vitro mineralization after overexpression of the osteoblast-specific transcription factor Runx2/Cbfa1. J Bone Miner Res 17:1931-1944.
6. Byers BA, Guldberg RE, Garcia AJ. 2004. Synergy between genetic and tissue engineering: Runx2 overexpression and in vitro construct development enhance in vivo mineralization. Tissue Eng 10:1757-1766.
7. Chen S, Guttridge DC, Tang E, Shi S, Guan K, Wang CY. 2001. Suppression of tumor necrosis factor-mediated apoptosis by nuclear factor kappaB-independent bone morphogenetic protein/Smad signaling. J Biol Chem 276:39259-39263.
8. Choi KY, Kim HJ, Lee MH, Kwon TG, Nah HD, Furuichi T, Komori T, Nam SH, Kim YJ, Kim HJ, Ryoo HM. 2005. Runx2 regulates FGF2-induced Bmp2 expression during cranial bone development. Dev Dyn 233:115-121.
9. Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425:577-584.
10. Doll B, Sfeir C, Winn S, Huard J, Hollinger J. 2001. Critical aspects of tissue-engineered therapy for bone regeneration. Crit Rev Eukaryot Gene Expr 11:173-198.
11. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. 1997. Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation. Cell 89:747-754.
12. Finkemeier CG. 2002. Bone-grafting and bone-graft substitutes. J Bone Joint Surg Am 84-A 454-464.
13. Franceschi RT, Yang S, Rutherford RB, Krebsbach PH, Zhao M, Wang D. 2004. Gene therapy approaches for bone regeneration. Cells Tissues Organs 176:95-108.
14. Gafni Y, Pelled G, Zilberman Y, Turgeman G, Apparailly F, Yotvat H, Galun E, Gazit Z, Jorgensen C, Gazit D. 2004. Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol Ther 9:587-595.
15. Gazit D, Turgeman G, Kelley P, Wang E, Jalenak M, Zilberman Y, Moutsatsos I. 1999. Engineered pluripotent mesenchymal cells integrate and differentiate in regenerating bone: A novel cell-mediated gene therapy. J Gene Med 1:121-133.
16. Gersbach CA, Byers BA, Pavlath GK, Garcia AJ. 2004a. Runx2/Cbfa1 stimulates transdifferentiation of primary skeletal myoblasts into a mineralizing osteoblastic phenotype. Exp Cell Res 300:406-417.
17. Gersbach CA, Byers BA, Pavlath GK, Guldberg RE, Garcia AJ. 2004b. Runx2/Cbfa1-genetically engineered skeletal myoblasts mineralize collagen scaffolds in vitro. Biotechnol Bioeng 88:369-378.
18. Gersbach CA, Le Doux JM, Guldberg RE, Garcia AJ. 2006. Inducible regulation of Runx2-stimulated osteogenesis. Gene Ther 13:873-882.
19. Helvering LM, Sharp RL, Ou X, Geiser AG. 2000. Regulation of the promoters for the human bone morphogenetic protein 2 and 4 genes. Gene 256:123-138.
20. Hildebrand T, Laib A, Muller R, Dequeker J, Ruegsegger P. 1999. Direct three-dimensional morphometric analysis of human cancellous bone: Microstructural data from spine, femur, iliac crest, and calcaneus. J Bone Miner Res 14:1167-1174.
21. Hirata K, Tsukazaki T, Kadowaki A, Furukawa K, Shibata Y, Moriishi T, Okubo Y, Bessho K, Komori T, Mizuno A, Yamaguchi A. 2003. Transplantation of skin fibroblasts expressing BMP-2 promotes bone repair more effectively than those expressing Runx2. Bone 32:502-512.
22. Hosseihkhani H, Azzam T, Kobayashi H, Hiraoka Y, Shimokawa H, Domb AJ, Tabata Y. 2006. Combination of 3D tissue engineered scaffold and non-viral gene carrier enhance in vitro DNA expression of mesenchymal stem cells. Biomaterials 27:4269-4278.
23. Hou Z, Nguyen Q, Frenkel B, Nilsson SK, Milne M, Van Wijnen AJ, Stein JL, Quesenberry P, Lian JB, Stein GS. 1999. Osteoblast-specific gene expression after transplantation of marrow cells: Implications for skeletal gene therapy. Proc Natl Acad Sci USA 96:7294-7299.
24. Huang W, Carlsen B, Wulur I, Rudkin G, Ishida K, Wu B, Yamaguchi DT, Miller TA. 2004. BMP-2 exerts differential effects on differentiation of rabbit bone marrow stromal cells grown in two-dimensional and three-dimensional systems and is required for in vitro bone formation in a PLGA scaffold. Exp Cell Res 299:325-334.
25. Ide H, Yoshida T, Matsumoto N, Aoki K, Osada Y, Sugimura T, Terada M. 1997. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 57:5022-5027.
26. Ito H, Koefoed M, Tiyapatanaputi P, Gromov K, Goater JJ, Carmouche J, Zhang X, Rubery PT, Rabinowitz J, Samulski RJ, Nakamura T, Soballe K, O'Keefe RJ, Boyce BF, Schwarz EM. 2005. Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med 11:291-297.
27. Jane JA, Jr., Dunford BA, Kron A, Pittman DD, Sasaki T, Li JZ, Li H, Alden TD, Dayoub H, Hankins GR, Kallmes DF, Helm GA. 2002. Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther 6:464-470.
28. Jankowski RJ, Deasy BM, Huard J. 2002. Muscle-derived stem cells. Gene Ther 9:642-647.
29. Kaihara S, Bessho K, Okubo Y, Sonobe J, Kawai M, Iizuka T. 2004. Simple and effective osteoinductive gene therapy by local injection of a bone morphogenetic protein-2-expressing recombinant adenoviral vector and FK506 mixture in rats. Gene Ther 11:439-447.
30. Kale S, Biermann S, Edwards C, Tarnowski C, Morris M, Long MW. 2000. Three-dimensional cellular development is essential for ex vivo formation of human bone. Nat Biotechnol 18:954-958.
31. Koefoed M, Ito H, Gromov K, Reynolds DG, Awad HA, Rubery PT, Ulrich-Vinther M, Soballe K, Guldberg RE, Lin AS, O'Keefe RJ, Zhang X, Schwarz EM. 2005. Biological effects of rAAV-caAlk2 coating on structural allograft healing. Mol Ther 12:212-218.
32. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. 1997. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764.
33. Krebsbach PH, Gu K, Franceschi RT, Rutherford RB. 2000. Gene therapy-directed osteogenesis: BMP-7-transduced human fibroblasts form bone in vivo. Hum Gene Ther 11:1201-1210.
34. Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM, Sung JH, Wozney JM, Kim HJ, Ryoo HM. 2003. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-{beta}1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 278:34387-34394.
35. Li JZ, Li H, Hankins GR, Dunford B, Helm GA. 2005. Local immunomodulation with CD4 and CD8 antibodies, but not cyclosporine A, improves osteogenesis induced by ADhBMP9 gene therapy. Gene Ther 12:1235-1241.
36. Lian JB, Stein GS. 2003. Runx2/Cbfa1: A multifunctional regulator of bone formation. Curr Pharm Des 9:2677-2685.
37. Moutsatsos IK, Turgeman G, Zhou S, Kurkalli BG, Pelled G, Tzur L, Kelley P, Stumm N, Mi S, Muller R, Zilberman Y, Gazit D. 2001. Exogenously regulated stem cell-mediated gene therapy for bone regeneration. Mol Ther 3:449-461.
38. Mueller SM, Glowacki J. 2001. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem 82:583-590.
39. Murphy TJ, Pavlath GK, Wang X, Boss V, Abbott KL, Robida AM, Nichols J, Xu K, Ellington ML, Loss JR. 2002. Retroviral vectors applied to gene regulation studies. Methods Enzymol 345:539-551.
40. Musgrave DS, Bosch P, Ghivizzani S, Robbins PD, Evans CH, Huard J. 1999. Adenovirus-mediated direct gene therapy with bone morphogenetic protein-2 produces bone. Bone 24:541-547.
41. Nishimura R, Hata K, Harris SE, Ikeda F, Yoneda T. 2002. Core-binding factor alpha 1 (Cbfa1) induces osteoblastic differentiation of C2C12 cells without interactions with Smad1 and Smad5. Bone 31:303-312.
42. Peng H, Usas A, Gearhart B, Young B, Olshanski A, Huard J. 2004. Development of a self-inactivating tet-on retroviral vector expressing bone morphogenetic protein 4 to achieve regulated bone formation. Mol Ther 9:885-894.
43. Peng H, Usas A, Hannallah D, Olshanski A, Cooper GM, Huard J. 2005. Noggin improves bone healing elicited by muscle stem cells expressing inducible BMP4. Mol Ther 12:239-246.
44. Perry CR. 1999. Bone repair techniques, bone graft, and bone graft substitutes. Clin Orthop 360:71-86.
45. Phillips JE, Gersbach CA, Wojtowicz AM, Garcia AJ. 2006a. Glucocorticoid-induced osteogenesis is negatively regulated by Runx2/Cbfa1 serine phosphorylation. J Cell Sci 119:581-591.
46. Phillips JE, Hutmacher DW, Guldberg RE, Garcia AJ. 2006b. Mineralization capacity of Runx2/Cbfa1-genetically engineered fibroblasts is scaffold dependent. Biomaterials 27:5535-5545.
47. Phimphilai M, Zhao Z, Boules H, Roca H, Franceschi RT. 2006. BMP signaling is required for RUKX2-dependent induction of the osteoblast phenotype. J Bone Miner Res 21:637-646.
48. Pola E, Gao W, Zhou Y, Pola R, Lattanzi W, Sfeir C, Gambotto A, Robbins PD. 2004. Efficient bone formation by gene transfer of human LIM mineralization protein-3. Gene Ther 11:683-693.
49. Pouliot F, Blais A, Labrie C. 2003, Overexpression of a dominant negative type II bone morphogenetic protein receptor inhibits the growth of human breast cancer cells. Cancer Res 63:277-281.
50. Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, Choi JY, Komori T, Stein JL, Lian JB, Stein GS, Van Wijnen AJ. 2003. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res 63:5357-5362.
51. Rando TA, Blau HM. 1994. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 125:1275-1287.
52. Schmitt JM, Hwang K, Winn SR, Hollinger JO. 1999. Bone morphogenetic proteins: An update on basic biology and clinical relevance. J Orthop Res 17:269-278.
53. Shi S, Gronthos S, Chen S, Reddi A, Counter CM, Robey PG, Wang CY. 2002. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol 20:587-591.
54. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG, Kassem M. 2002. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol 20:592-596.
55. Springer ML, Blau HM. 1997. High-efficiency retroviral infection of primary myoblasts. Somat Cell Mol Genet 23:203-209.
56. Vaccaro AR. 2002. The role of the osteoconductive scaffold in synthetic bone graft. Orthopedics 25:s571-s578.
57. Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD, Franceschi RT. 2002. Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. J Bone Miner Res 17:101-110.
58. Yang S, Wei D, Wang D, Phimphilai M, Krebsbach PH, Franceschi RT. 2003. In vitro and in vivo synergistic interactions between the Runx2/Cbfa1 transcription factor and bone morphogenetic protein-2 in stimulating osteoblast differentiation. J Bone Miner Res 18:705-715.
59. Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P. 2005. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res 65:5769-5777.
60. Yoon ST, Boden SD. 2002. Osteoinductive molecules in orthopaedics: Basic science and preclinical studies. Clin Orthop 395:33-43.
61. Zhao M, Zhao Z, Koh JT, Jin T, Franceschi RT. 2005a. Combinatorial gene therapy for bone regeneration: Cooperative interactions between adenovirus vectors expressing bone morphogenetic proteins 2, 4, and 7. J Cell Biochem 95:1-16.
62. Zhao Z, Zhao M, Xiao G, Franceschi RT. 2005b. Gene transfer of the Runx2 transcription factor enhances osteogenic activity of bone marrow stromal cells in vitro and in vivo. Mol Ther 12:247-253.
63. Zheng H, Guo Z, Ma Q, Jia H, Dang G. 2004. Cbfa1/osf2 transduced bone marrow stromal cells facilitate bone formation in vitro and in vivo. Calcif Tissue Int 74:194-203.